Worldwide, more than a million breast cancer patients have been treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, which slow or stop the uncontrolled multiplication of cancer cells. Researchers see untapped potential in those targeted therapies, which can dramatically extend progression-free survival—the time before the disease grows worse—and overall survival, even in metastatic disease. Could those benefits be extended to patients with other types of cancer?
The Verdict
ClassificationLikely AI
ConfidenceHigh confidence
Analyzedtext, image
ImageAI Generated
Community Verdict
Sign in to vote
Be the first to vote on this assessment.
Embed Badge
Add this badge to your site to show the AI classification for this content.
[](https://real.press/content/76263bd1-c313-497c-ad34-3de88fa8bd60)